Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review.

IF 1.8 4区医学 Q3 RHEUMATOLOGY

Modern Rheumatology Pub Date : 2024-12-25 DOI:10.1093/mr/roae046

Kenichi Nishimura, Takashi Ishikawa, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori

{"title":"Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: A systematic review.","authors":"Kenichi Nishimura, Takashi Ishikawa, Nami Okamoto, Keiji Akamine, Natsumi Inoue, Hitoshi Irabu, Kentaro Kato, Hiroshi Keino, Masayo Kojima, Hiroshi Kubo, Kazuichi Maruyama, Mao Mizuta, Kosuke Shabana, Masaki Shimizu, Yuko Sugita, Yukiko Takakuwa, Satoshi Takanashi, Hiroshi Takase, Hiroaki Umebayashi, Natsuka Umezawa, Shingo Yamanishi, Kazuko Yamazaki, Masato Yashiro, Takahiro Yasumi, Masaaki Mori","doi":"10.1093/mr/roae046","DOIUrl":null,"url":null,"abstract":"Objectives: This systematic review assessed the efficacy and safety of abatacept in patients with systemic juvenile idiopathic arthritis (JIA).Methods: Studies published between 2000 and 2021 were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries. The risk of bias was assessed according to the manual for development clinical practice guidelines by Minds, a project to promote evidence-based medicine in Japan.Results: Seven observational studies were included. American College of Rheumatology pediatric 30/50/70 responses at 3, 6, and 12 months were 64.8%/50.3%/27.9%, 85.7%/71.4%/42.9%, and 80.0%/50.0%/40.0%, respectively. Outcomes on systemic symptoms, joint symptoms, and activities of daily living were not obtained. No macrophage activation syndrome or infusion reaction occurred. Serious infection occurred in 2.6% of cases.Conclusions: Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL-6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"167-173"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roae046","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This systematic review assessed the efficacy and safety of abatacept in patients with systemic juvenile idiopathic arthritis (JIA).

Methods: Studies published between 2000 and 2021 were searched using PubMed, Embase, Cochrane, Ichushi-Web, and clinical trial registries. The risk of bias was assessed according to the manual for development clinical practice guidelines by Minds, a project to promote evidence-based medicine in Japan.

Results: Seven observational studies were included. American College of Rheumatology pediatric 30/50/70 responses at 3, 6, and 12 months were 64.8%/50.3%/27.9%, 85.7%/71.4%/42.9%, and 80.0%/50.0%/40.0%, respectively. Outcomes on systemic symptoms, joint symptoms, and activities of daily living were not obtained. No macrophage activation syndrome or infusion reaction occurred. Serious infection occurred in 2.6% of cases.

Conclusions: Abatacept improved the disease activity index. In addition, abatacept was as safe as interleukin-6 (IL-6) and IL-1 inhibitors. However, both the efficacy and safety data in this systematic review should be reviewed with caution because their quality of evidence is low or very low. Further studies are needed to confirm the efficacy and safety of abatacept for systemic JIA, especially its efficacy on joint symptoms.

查看原文本刊更多论文

阿帕他赛治疗全身性幼年特发性关节炎的疗效和安全性：系统性综述。

目的：对阿帕赛普治疗全身性幼年特发性关节炎（JIA）患者的疗效和安全性进行评估：本系统综述评估了阿帕他赛对全身性幼年特发性关节炎（JIA）患者的疗效和安全性：方法：通过PubMed、Embase、Cochrane、Ichushi-Web和临床试验登记处检索2000年至2021年间发表的研究。结果：共纳入7项观察性研究：结果：共纳入七项观察性研究。美国风湿病学会儿科 30/50/70 在 3、6 和 12 个月时的应答率分别为 64.8%/50.3%/27.9%、85.7%/71.4%/42.9% 和 80.0%/50.0%/40.0%。未获得有关全身症状、关节症状和日常生活能力的结果。未出现巨噬细胞活化综合征或输液反应。2.6%的病例发生了严重感染：阿巴他赛普改善了疾病活动指数。此外，阿帕他赛与白细胞介素-6（IL-6）和IL-1抑制剂一样安全。然而，由于证据质量较低或很低，因此应谨慎审查本系统综述中的疗效和安全性数据。阿帕他赛对全身性JIA的疗效和安全性，尤其是对关节症状的疗效，还需要进一步研究证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Modern Rheumatology RHEUMATOLOGY-

CiteScore

4.90

自引率

9.10%

发文量

146

审稿时长

1.5 months

期刊介绍： Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions